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TWICE-WEEKLY ABLC PROPHYLAXIS FOR PATIENTS AT HIGH RISK OF
INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Jansen, J., Akard, L.P., Wack, M.F., Thompson, J.M., Dugan, M.J.,
Leslie, J.K., Mattison, R.H. Indiana Blood and Marrow Transplanta-
tion, Indianapolis, IN.
Invasive fungal infections (IFIs) are increasing after allogeneic
stem cell transplantation (aSCT). Known prognostic factors for IFI
include mismatched donors, severe GvHD, CMV infection, and
the use of steroids. Our group treated all patients during their
initial neutropenic episode with oral ﬂuconazole or itraconazole
(200–400 mg/day). Starting on day 30, patients who received
prednisone  30 mg/day were switched to intravenous amphoter-
icin-B lipid complex (ABLC; Abelcet) at a dosage of 4 mg/kg twice
a week. Patients who received lower steroid doses continued their
ﬂuconazole/itraconazole until at least day 100 after SCT. Be-
tween 1999 and 2002, a total of 100 patients were enrolled, includ-
ing 24 patients with unrelated donors and 11 patients with partially
mismatched related donors. Good-risk patients were a minority
(27%), whereas 32% had overt relapse and/or refractory disease.
Preparative regimens contained TBI (45%), busulfan/cyclophos-
phamide (35%), or ﬂudarabine (20%). BM and PBSC were the
source of stem cells in 43% and 57% of patients, respectively.
Prophylaxis of aGvHD was based on cyclosporine but included
steroids in 27%, in vivo T-cell depletion in 25%, and in vitro
T-cell depletion in 15% of patients. Out of 37 patients who did not
receive ABLC prophylaxis, 2 developed IFI beyond day 30 (1
from Aspergillus on day 36, 1 from Candida on day 63). A total
of 63 patients did receive prophylactic ABLC for a median of 52
days (range, 1 to 289 days). Six of the patients at such high risk of
IFI that they were assigned to ABLC prophylaxis still developed
IFI (3 from Aspergillus at days 45, 65, and 255 and 3 from
Candida at days70,72, and210). An additional 2 patients had
probable, but undocumented, IFI. Univariate analysis of all pa-
tients with IFI showed that factors increasing the risk of IFI were
BM as the stem cell source, MUD or PMRD, severe GvHD, and
CMV infection (P  .01 in all comparisons). Interestingly, the use
of steroids (and/or use of ABLC) was no longer a prognostic
parameter. The twice-weekly ABLC was well tolerated, with a
median increase in creatinine of 0.85 mg/dL.
This regimen of twice-weekly intravenous ABLC 4 mg/kg ap-
pears to compensate for the increased risk of IFI associated with
the use of steroids after allogeneic SCT. This prophylaxis resulted
in a low incidence of IFI in this analysis of 100 allograft recipients
and allowed the use of higher doses of steroids. To increase its
early efﬁcacy, the twice-weekly ABLC prophylaxis perhaps should
be started earlier than day 30.
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AMD3100 PLUS G-CSF RAPIDLY MOBILIZES HEMATOPOIETIC PRO-
GENITOR CELLS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA
(NHL) AND MULTIPLE MYELOMA (MM), INCLUDING THOSE TRADI-
TIONALLY CONSIDERED “POOR MOBILIZERS”
Stiff, P.1, Micallef, I.2, McCarthy, P.3, Magalhaes-Silverman, M.4,
Fromenberg, N.5, Weisdorf, D.6, Tricot, G.7, Territo, M.8,
Abodnour, R.9, Badel, K.10, Calandra, G.10 1Loyola University Medical
Center, Maywood, IL; 2Mayo Clinic, Rochester, MN; 3Roswell Park
Memorial Institute, Buffalo, NY; 4University of Iowa, Iowa City, IA;
5Thomas Jefferson University, Philadelphia, PA; 6University of Minne-
sota, Minneapolis, MN; 7University of Arkansas, Little Rock, AK;
8University of California Los Angeles, Los Angeles, CA; 9University of
Indiana, Indianapolis, IN; 10ArnorMed Inc., Langley, BC, Canada.
AMD3100 is a potent, selective antagonist of the CXCR4 che-
mokine receptor, blocking binding of its cognate ligand, stromal
cell–derived factor 1	. Administration leads to elevations in circu-
lating hematopoietic progenitor cells after 10–11 hours. Prelimi-
nary studies showed that more progenitor cells were mobilized into
the circulation when G-CSF and AMD 3100 were administered to
patients compared to G-CSF administration alone. To investigate
the degree of progenitor cell mobilization of AMD3100 and G-
CSF (10 g/kg/day), we treated unselected patients undergoing
autotransplantation for NHL and MM. G-CSF at 10 g/kg/day
for up to 9 days was administered SQ with AMD3100 at 240
g/kg/day SQ starting on the evening of day 4 of G-CSF (10–11
hours before planned daily aphereses) until 5 106 CD34/kg were
collected, or to a maximum of 5 days of a standard 3 blood volume
apheresis. Of 43 patients entered to date, 20 (6 myeloma, 14 NHL)
have been analyzed. Of these 20, 14 are considered to have been
heavily pretreated using standard deﬁnitions (10 cycles of chemo-
therapy, platinum-based salvage chemotherapy, and/or radiation
therapy to bone marrow sites).
Blood CD34 assays (cells/L) were performed before and after
each AMD 3100 dose and on each apheresis product. After the ﬁrst
dose of AMD3100 there were 2.6-fold and 3.0-fold increases in
CD34 cells/L in blood for the NHL and MM patients, respec-
tively. A median 2 aphereses were performed (range, 1–5); the
median total CD34 collected was 5.7  106/kg (range, 2.32–
14.58  106/kg). All patients had collections of  2.0  106 CD34
cells/kg, and in 14, the 5  106 CD34/kg cell dose goal was
collected, including 8 of 14 in the heavily pretreated group. In 6
patients, the 5  106 CD34/kg cell dose was collected in a single
apheresis. The median CD34/kg cell dose collected for the 14
heavily pretreated patients was 6.0  106/kg.
There were no serious adverse eeffects related to the use of
AMD3100. Transient diarrhea occurred in 44% shortly after the
injections of AMD3100, but only 3 patients required therapy.
Engraftment data for the ﬁrst 12 patients treated demonstrated
time to ANC  500/L and platelets  20,000/L of 9 days
(range, 8–10) and 12 days (range, 9–19), respectively.
The combination of AMD3100 and G-CSF appears to be effec-
tive in mobilizing large numbers of CD34 cells, and appears
superior to G-CSF alone in heavily pretreated patients, in whom it
appears to be a potentially less-toxic alternative to chemotherapy/
cytokine mobilization.
272
INFLUENCE OF IMMUNOSUPPRESSIVE AGENTS ON MAGNESIUM (MG)
METABOLISM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT): COMPARISON BETWEEN CYCLOSPORINE
A (CSA) AND TACROLIMUS
Aisa, Y., Mori, T., Shimizu, T., Yamazaki, R., Yamane, A., Adachi, A.,
Yokoyama, A., Nakazato, T., Ikeda, Y., Okamoto, S. Keio University
School of Medeicine, Tokyo, Japan.
Background: Calcineurin inhibitors, CSA and tacrolimus, are
universally used for the prophylaxis and treatement of graft-versus-
host disease (GVHD) after allogeneic HSCT. In addition to their
common adverse effects, including renal dysfunction, CSA and
tacrolimus cause hypomagnesemia due to the suppression of reab-
sorption of Mg from renal tubules. Because hypomagnesemia has
reportedly been associated with renal dysfunction and encephalop-
athy by CSA and tacrolimus, strict monitoring and management of
serum Mg level are necessary. We performed a prospective study
to evaluate Mg metabolism in recipients of allogeneic HSCT who
were receiving CSA or tacrolimus. Methods: Consecutive patients
undergoing allogeneic HSCT at Keio University Hospital between
January 2003 and July 2004 were enrolled. CSA (3 mg/kg/day) and
tacrolimus (0.03 mg/kg/day) were administered intravenously by
continuous infusion starting from day 1. The doses were ar-
ranged to maintain blood levels at 200–400 ng/mL for CSA and at
15–20 ng/mL for tacrolimus. Serum Mg and the total amount of
daily Mg excretion in urine were measured once before the admin-
istration of CSA or tacrolimus, and then once weekly after HSCT
for 4 weeks. Mg was supplemented intravenously by continuous
infusion to maintain the serum Mg level  1.5 mEq/L. Results:
Thirty-six patients were evaluable (12 in the CSA group and 24 in
the tacrolimus group). The serum Mg level began to decrease in
both groups from the ﬁrst week after HSCT, and was signiﬁcantly
lower in the tacrolimus group than in the CSA group from the ﬁrst
to the third weeks (P  .01). The total amount of daily Mg
excretion in urine and Mg supplementation began to increase in
both groups from the second week after HSCT, and they were
signiﬁcantly higher in the tacrolimus group than in the CSA group
(P  .01). Conclusions: Although both CSA and tacrolimus in-
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